The European Medicines Agency (EMA) is set to move into its new temporary headquarters in Amsterdam in early March, after it closes its London office on 1 March, but is anticipating a substantial loss of staff due to the relocation.
Until the move, the EMA plans to conduct its daily business and continue with phase 4 of its business continuity plan. The objectives include the authorization, maintenance, and supervision of medicines; ongoing Brexit preparedness/implementation activities; and preparing for new veterinary legislation. The EMA also will make adjustments in regard to an anticipated 25% loss of its total workforce to maintain services during the peak relocation time.
Once the EMA has completed its move to its temporary home in the Spark building in Sloterdijk, the organization plans to review other activities from its multiannual work plan to resume in the second half of 2019.
The EMA's new address is European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands.
As of 15 March, all EMA meetings will take place at the Spark building. The dates for scientific committee meetings will remain the same.
